Literature DB >> 34184154

Perspectives on glucocorticoid usage in patients with adult inflammatory myopathy.

Jesús Loarce-Martos1, James B Lilleker2,3, Eve Alder2, Jo Goode4, Hector Chinoy5,6.   

Abstract

This study aims to describe the patient perspective on glucocorticoid (GC) treatment and adverse effects (AEs) in idiopathic inflammatory myopathy (IIM). An online survey was distributed to patients with adult-onset IIM using the Myositis UK page on Healthunlocked.com, an online social network for health. Respondents were asked to rate the severity of AEs they attributed to GCs on a Likert scale (0-5), and to report concerns and overall experience of GC treatment. The survey was completed by 122 respondents. The median reported current daily dose of prednisolone was 15 mg (interquartile range [IQR] 8, 25) and median treatment duration 5.3 years (IQR 3.4, 8.0) at the time of survey completion. Only 54% of respondents "agreed" or "strongly agreed" that the information provided to them about GC treatment was adequate. AEs rated most severe by respondents were weight gain, moon face, sleep disturbances and increased hunger. The duration of GC treatment weakly correlated with the mean number of reported AEs (p = 0.004) and mean severity of AEs (p = 0.017). There was an inverse relationship between age and acne, stretch marks, hair loss, facial hair, nausea and heartburn (p < 0.05). In this first study of patient-reported experiences of GCs specifically in IIM, we describe the burden of treatment and highlight the unmet need for safe and well-tolerated treatments. We report that patients with IIM often remain on long-term GC treatment at moderate doses, and that AEs are common. The reported data will be useful in planning discussions with patients regarding adherence to their treatment options. Key Points • Glucocorticoids (GC) are the first-line treatment in patients with idiopathic inflammatory myopathies (IIM), and are associated with a wide range of adverse effects • The adverse effects related to GC are very common, and those reported most severe by patients included weight gain, moon face, increased hunger or sleep disturbance, which may differ from the primary concerns of their treating clinician • Understanding the patient perspective and concerns about treatment is necessary to maintain a good physician-patient relationship and may help with treatment adherence.

Entities:  

Keywords:  Dermatomyositis; Glucocorticoids; Patient-reported outcome measures; Polymyositis

Year:  2021        PMID: 34184154     DOI: 10.1007/s10067-021-05767-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  13 in total

1.  Understanding the side effects of glucocorticoid therapy: shining a light on a drug everyone thinks they know.

Authors:  William G Dixon; Nick Bansback
Journal:  Ann Rheum Dis       Date:  2012-07-31       Impact factor: 19.103

2.  Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis.

Authors:  Rohit Aggarwal; Galina Marder; Diane Carol Koontz; Preeya Nandkumar; Zengbiao Qi; Chester V Oddis
Journal:  Ann Rheum Dis       Date:  2017-12-13       Impact factor: 19.103

3.  Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up.

Authors:  K P Ng; F Ramos; S M Sultan; D A Isenberg
Journal:  Clin Rheumatol       Date:  2009-04-23       Impact factor: 2.980

4.  Development of the Systemic Lupus Erythematosus Steroid Questionnaire (SSQ): a novel patient-reported outcome tool to assess the impact of oral steroid treatment.

Authors:  Susan D Mathias; Pamela Berry; Jane De Vries; Anca Askanase; Katie Pascoe; Hilary H Colwell; David J Chang
Journal:  Health Qual Life Outcomes       Date:  2017-02-28       Impact factor: 3.186

5.  Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Joanna C Robson; Jill Dawson; Peter F Cronholm; Susan Ashdown; Ebony Easley; Katherine S Kellom; Don Gebhart; Georgia Lanier; Nataliya Milman; Jacqueline Peck; Raashid A Luqmani; Judy A Shea; Gunnar Tomasson; Peter A Merkel
Journal:  Rheumatol Int       Date:  2017-11-09       Impact factor: 2.631

Review 6.  Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines [corrected].

Authors:  Alain Meyer; Carlo Alberto Scirè; Rosaria Talarico; Tobias Alexander; Zahir Amoura; Tadej Avcin; Simone Barsotti; Lorenzo Beretta; Jelena Blagojevic; Gerd Burmester; Ilaria Cavazzana; Patrick Cherrin; Laura Damian; Andrea Doria; João Eurico Fonseca; Federica Furini; Ilaria Galetti; Frederic Houssiau; Thomas Krieg; Larosa Maddalena; David Launay; Raquel Campanilho-Marques; Thierry Martin; Marco Matucci-Cerinic; Pia Moinzadeh; Carlomaurizio Montecucco; Maria Francisca Moraes-Fontes; Luc Mouthon; Rossella Neri; Sabrina Paolino; Yves Piette; Simona Rednic; Farah Tamirou; Angela Tincani; Natasa Toplak; Stefano Bombardieri; Eric Hachulla; Ulf Mueller-Ladner; Matthias Schneider; Vanessa Smith; Ana Vieira; Maurizio Cutolo; Marta Mosca; Lorenzo Cavagna
Journal:  RMD Open       Date:  2019-02-26

7.  Perspectives of Glucocorticoid Use in Patients with Rheumatoid Arthritis.

Authors:  Gabriella Venter; Joanna Tieu; Rachel Black; Susan Lester; Nieves Leonardo; Samuel L Whittle; Elizabeth Hoon; Claire Barrett; Debra Rowett; Rachelle Buchbinder; Catherine L Hill
Journal:  ACR Open Rheumatol       Date:  2021-02-20

Review 8.  Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force.

Authors:  Cindy Strehl; Johannes W J Bijlsma; Maarten de Wit; Maarten Boers; Nele Caeyers; Maurizio Cutolo; Bhaskar Dasgupta; William G Dixon; Rinie Geenen; Tom W J Huizinga; Alison Kent; Annette Ladefoged de Thurah; Joachim Listing; Xavier Mariette; David W Ray; Hans U Scherer; Raphaèle Seror; Cornelia M Spies; Simon Tarp; Dieter Wiek; Kevin L Winthrop; Frank Buttgereit
Journal:  Ann Rheum Dis       Date:  2016-03-01       Impact factor: 19.103

9.  The EuroMyositis registry: an international collaborative tool to facilitate myositis research.

Authors:  James B Lilleker; Jiri Vencovsky; Guochun Wang; Lucy R Wedderburn; Louise Pyndt Diederichsen; Jens Schmidt; Paula Oakley; Olivier Benveniste; Maria Giovanna Danieli; Katalin Danko; Nguyen Thi Phuong Thuy; Monica Vazquez-Del Mercado; Helena Andersson; Boel De Paepe; Jan L deBleecker; Britta Maurer; Liza J McCann; Nicolo Pipitone; Neil McHugh; Zoe E Betteridge; Paul New; Robert G Cooper; William E Ollier; Janine A Lamb; Niels Steen Krogh; Ingrid E Lundberg; Hector Chinoy
Journal:  Ann Rheum Dis       Date:  2017-08-30       Impact factor: 19.103

10.  Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study.

Authors:  Johan Lim; Filip Eftimov; Camiel Verhamme; Esther Brusse; Jessica E Hoogendijk; Christiaan G J Saris; Joost Raaphorst; Rob J De Haan; Ivo N van Schaik; Eleonora Aronica; Marianne de Visser; Anneke J van der Kooi
Journal:  Rheumatology (Oxford)       Date:  2021-04-06       Impact factor: 7.580

View more
  1 in total

Review 1.  Glucocorticoids in Myositis: Initiation, Tapering, and Discontinuation.

Authors:  Didem Saygin; Chester V Oddis
Journal:  Curr Rheumatol Rep       Date:  2022-03-11       Impact factor: 4.592

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.